BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Prognosis
10 results:

  • 1. Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance.
    Kuang L; Zhang J; Li Y; Wang Q; Liu J; Zhang B
    BMC Womens Health; 2024 Mar; 24(1):188. PubMed ID: 38515066
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.
    Feng S; Ding B; Dai Z; Yin H; Ding Y; Liu S; Zhang K; Lin H; Xiao Z; Shen Y
    J Transl Med; 2024 Mar; 22(1):280. PubMed ID: 38491511
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry.
    Mueller SH; Lai AG; Valkovskaya M; Michailidou K; Bolla MK; Wang Q; Dennis J; Lush M; Abu-Ful Z; Ahearn TU; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Augustinsson A; Baert T; Freeman LEB; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Bonanni B; Brenner H; Brucker SY; Buys SS; Castelao JE; Chan TL; Chang-Claude J; Chanock SJ; Choi JY; Chung WK; ; Colonna SV; ; Cornelissen S; Couch FJ; Czene K; Daly MB; Devilee P; Dörk T; Dossus L; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Engel C; Evans DG; Fasching PA; Fletcher O; Flyger H; Gago-Dominguez M; Gao YT; García-Closas M; García-Sáenz JA; Genkinger J; Gentry-Maharaj A; Grassmann F; Guénel P; Gündert M; Haeberle L; Hahnen E; Haiman CA; Håkansson N; Hall P; Harkness EF; Harrington PA; Hartikainen JM; Hartman M; Hein A; Ho WK; Hooning MJ; Hoppe R; Hopper JL; Houlston RS; Howell A; Hunter DJ; Huo D; ; Ito H; Iwasaki M; Jakubowska A; Janni W; John EM; Jones ME; Jung A; Kaaks R; Kang D; Khusnutdinova EK; Kim SW; Kitahara CM; Koutros S; Kraft P; Kristensen VN; Kubelka-Sabit K; Kurian AW; Kwong A; Lacey JV; Lambrechts D; Le Marchand L; Li J; Linet M; Lo WY; Long J; Lophatananon A; Mannermaa A; Manoochehri M; Margolin S; Matsuo K; Mavroudis D; Menon U; Muir K; Murphy RA; Nevanlinna H; Newman WG; Niederacher D; O'Brien KM; Obi N; Offit K; Olopade OI; Olshan AF; Olsson H; Park SK; Patel AV; Patel A; Perou CM; Peto J; Pharoah PDP; Plaseska-Karanfilska D; Presneau N; Rack B; Radice P; Ramachandran D; Rashid MU; Rennert G; Romero A; Ruddy KJ; Ruebner M; Saloustros E; Sandler DP; Sawyer EJ; Schmidt MK; Schmutzler RK; Schneider MO; Scott C; Shah M; Sharma P; Shen CY; Shu XO; Simard J; Surowy H; Tamimi RM; Tapper WJ; Taylor JA; Teo SH; Teras LR; Toland AE; Tollenaar RAEM; Torres D; Torres-Mejía G; Troester MA; Truong T; Vachon CM; Vijai J; Weinberg CR; Wendt C; Winqvist R; Wolk A; Wu AH; Yamaji T; Yang XR; Yu JC; Zheng W; Ziogas A; Ziv E; Dunning AM; Easton DF; Hemingway H; Hamann U; Kuchenbaecker KB
    Genome Med; 2023 Jan; 15(1):7. PubMed ID: 36703164
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors.
    Wang B; Tang Q; Xu L; Teng X; Ding W; Ren G; Wang X
    Mod Pathol; 2021 Jan; 34(1):42-50. PubMed ID: 32732929
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Co-expressed functional module-related genes in ovarian cancer stem cells represent novel prognostic biomarkers in ovarian cancer.
    Gov E
    Syst Biol Reprod Med; 2020 Aug; 66(4):255-266. PubMed ID: 32441533
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. MiR-628-5p decreases the tumorigenicity of epithelial ovarian cancer cells by targeting at fgfr2.
    Li M; Qian Z; Ma X; Lin X; You Y; Li Y; Chen T; Jiang H
    Biochem Biophys Res Commun; 2018 Jan; 495(2):2085-2091. PubMed ID: 29229394
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. fgfr2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Jeske YW; Ali S; Byron SA; Gao F; Mannel RS; Ghebre RG; DiSilvestro PA; Lele SB; Pearl ML; Schmidt AP; Lankes HA; Ramirez NC; Rasty G; Powell M; Goodfellow PJ; Pollock PM
    Gynecol Oncol; 2017 May; 145(2):366-373. PubMed ID: 28314589
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.
    Timsah Z; Ahmed Z; Ivan C; Berrout J; Gagea M; Zhou Y; Pena GN; Hu X; Vallien C; Kingsley CV; Lu Y; Hancock JF; Liu J; Gladden AB; Mills GB; Lopez-Berestein G; Hung MC; Sood AK; Bogdanov M; Ladbury JE
    Oncogene; 2016 Apr; 35(17):2186-96. PubMed ID: 26212011
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
    Spaans VM; Trietsch MD; Crobach S; Stelloo E; Kremer D; Osse EM; Haar NT; van Eijk R; Muller S; van Wezel T; Trimbos JB; Bosse T; Smit VT; Fleuren GJ
    PLoS One; 2014; 9(3):e93451. PubMed ID: 24671188
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
    Byron SA; Loch DC; Pollock PM
    Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.